Day OneTuesday, 29 April 2025 - GMT (Greenwich Mean Time, GMTZ)

M&A Masterclass

Part 1: Deep Dive into the Current M&A Landscape

• Overview of the Pharma M&A Landscape
  • Current trends and statistics in pharma M&A
  • Impact of recent M&A deals on the industry
• Importance of M&A for Biotechs
  • How M&A can provide biotechs with resources, market access, and expertise
  • Strategies for biotechs to position themselves as attractive targets or acquirers
• Key Considerations for Successful Transactions
  • Essential elements of due diligence, valuation methods, and metrics
  • Importance of cultural fit and post-acquisition integration

Part 2: How to Turn a 10-Person Biotech into a $1.1Bn Acquisition in 7 Years

Presented by Renee Aguiar-Lucander, CEO, Calliditas

• Motivation Behind the Acquisition
• Process Overview
• Outcome and Lessons Learned
• Future Considerations

Part 3:

• Open Floor for Questions
  • How to prepare a biotech company for M&A discussions?
  • What specific attributes do buyers look for in a biotech firm?
  • How can biotechs leverage M&A as a growth strategy?
• Wrap-Up Discussion
  • Summarize key takeaways from the workshop.
  • Highlight actionable insights for biotech companies considering M&A

IPO Masterclass

Part 1: Understanding the IPO Landscape

• Overview of the IPO Market
  • Current trends and statistics in biotech IPOs
  • Key factors driving IPO activity in the sector
• Advantages and Challenges of Going Public
  • Access to capital, visibility, and credibility benefits
  • Regulatory, operational, and financial challenges associated with IPOs
• Pre-IPO Preparation
  • Key steps to ensure readiness, including financial audits and governance

Building a compelling investment story for investors

Part 2: Case Study – From Startup to IPO

• Strategic Decision to Pursue an IPO
• Navigating the IPO Process
• Key Outcomes and Lessons Learned
• Long-Term Strategies Post-IPO

Part 3:

Q&A and Discussion

• Open Floor for Questions
  • What are the most critical factors to consider when deciding to go public?
  • How should a biotech company approach investor relations post-IPO?
  • What are the best practices for maintaining stock performance after going public?
• Wrap-Up Discussion
  • Summarize the key insights and takeaways from the workshop
  • Highlight actionable steps for biotech companies in preparing for an IPO